Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer

Authors:

Abstract
Accurate assessment of toxic effects is an essential function in cancer clinical trials and routine care of cancer patients. In clinical trials, investigators commonly evaluate and quantify toxic effects and adverse events using the Common Terminology Criteria for Adverse Events (CTCAE) instrument developed by the National Cancer Institute.1 Emerging evidence suggests that direct patient reporting of symptoms may improve the accuracy and validity of toxic effects assessment.2 Disagreement between patient-reported and practitioner-reported symptomatic toxic effects has been extensively described3 and between-practitioner agreement in toxic effects ratings may also be only modest.4 There is evidence5,6 to suggest that, compared with practitioner reporting, patient-reported symptoms are more strongly correlated with clinical outcomes.

This publication has 25 references indexed in Scilit: